Literature DB >> 26802035

Prediction of regression of retinal neovascularisation after panretinal photocoagulation for proliferative diabetic retinopathy.

Irini P Chatziralli1, Theodoros N Sergentanis2, Sobha Sivaprasad3,4.   

Abstract

PURPOSE: The purpose of this study was to evaluate the regression of neovascularization elsewhere (NVE) after panretinal photocoagulation (PRP) based on its location in relation to the internal limiting membrane (ILM).
METHODS: Participants in this retrospective case series were 47 patients with active NVE within the vascular arcade. All patients were treated with PRP and followed up for at least 12 months. The time to regression of NVE based on its location relative to the ILM on spectral domain-optical coherence tomography (SD-OCT) was analyzed.
RESULTS: The proportion of eyes, showing regression of NVE at the end of follow-up period was 19/25 (76 %) in the "below ILM" group and 13/22 (59 %) in the "above ILM" group. The "below ILM" group was associated with a twofold enhanced regression of NVE in comparison to the "above ILM" group (HR = 2.13, p = 0.038).
CONCLUSIONS: Regression of NVE is determined by its location relative to the ILM. Patients with "below ILM" NVE were found to show a twofold increased regression rate in comparison with the "above ILM" group, while the proportion of eyes showing regression of NVE at the end of the follow-up period was significantly greater in the "below ILM" than the "above ILM" group.

Entities:  

Keywords:  Neovascularization; Photocoagulation; Proliferative diabetic retinopathy

Mesh:

Year:  2016        PMID: 26802035     DOI: 10.1007/s00417-016-3275-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  25 in total

1.  Panretinal photocoagulation for proliferative diabetic retinopathy: pattern scan laser versus argon laser.

Authors:  Aimee V Chappelow; Kevin Tan; Nadia K Waheed; Peter K Kaiser
Journal:  Am J Ophthalmol       Date:  2011-09-19       Impact factor: 5.258

2.  Optos-guided pattern scan laser (Pascal)-targeted retinal photocoagulation in proliferative diabetic retinopathy.

Authors:  Mahiul M K Muqit; George R Marcellino; David B Henson; Lorna B Young; Niall Patton; Stephen J Charles; George S Turner; Paulo E Stanga
Journal:  Acta Ophthalmol       Date:  2011-12-16       Impact factor: 3.761

Review 3.  Diabetic retinopathy.

Authors:  David A Antonetti; Ronald Klein; Thomas W Gardner
Journal:  N Engl J Med       Date:  2012-03-29       Impact factor: 91.245

4.  Swept-source optical coherence tomography imaging of the cortical vitreous and the vitreoretinal interface in proliferative diabetic retinopathy: assessment of vitreoschisis, neovascularisation and the internal limiting membrane.

Authors:  Mahiul M K Muqit; Paulo E Stanga
Journal:  Br J Ophthalmol       Date:  2014-03-21       Impact factor: 4.638

5.  Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1976-04       Impact factor: 5.258

6.  Three-dimensional vascular imaging of proliferative diabetic retinopathy by Doppler optical coherence tomography.

Authors:  Masahiro Miura; Young-Joo Hong; Yoshiaki Yasuno; Daisuke Muramatsu; Takuya Iwasaki; Hiroshi Goto
Journal:  Am J Ophthalmol       Date:  2014-12-09       Impact factor: 5.258

7.  Vitreous contraction in proliferative diabetic retinopathy.

Authors:  M D Davis
Journal:  Arch Ophthalmol       Date:  1965-12

8.  Prospective assessment of proliferative diabetic retinopathy with observations of posterior vitreous detachment.

Authors:  Ryuichiro Ono; Akihiro Kakehashi; Hiroko Yamagami; Norito Sugi; Nozomi Kinoshita; Takako Saito; Hiroyuki Tamemoto; Masatoshi Kuroki; San-E Lshikawa; Masanobu Kawakami
Journal:  Int Ophthalmol       Date:  2006-06-15       Impact factor: 2.031

9.  Retinal neovascularization secondary to proliferative diabetic retinopathy characterized by spectral domain optical coherence tomography.

Authors:  Hyung Cho; Ahmad A Alwassia; Caio V Regiatieri; Jason Y Zhang; Caroline Baumal; Nadia Waheed; Jay S Duker
Journal:  Retina       Date:  2013-03       Impact factor: 4.256

10.  Reevaluating the definition of intraretinal microvascular abnormalities and neovascularization elsewhere in diabetic retinopathy using optical coherence tomography and fluorescein angiography.

Authors:  Cecilia S Lee; Aaron Y Lee; Dawn A Sim; Pearse A Keane; Hemal Mehta; Javier Zarranz-Ventura; Marcus Fruttiger; Catherine A Egan; Adnan Tufail
Journal:  Am J Ophthalmol       Date:  2014-10-25       Impact factor: 5.258

View more
  5 in total

1.  The effect of vitreous on proliferative diabetic retinopathy and the response to panretinal photocoagulation.

Authors:  Irini P Chatziralli; Theodoros N Sergentanis; Sobha Sivaprasad
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-10-24       Impact factor: 3.117

2.  The effects of vitreous on proliferative diabetic retinopathy and the response to pan retinal photocoagulation.

Authors:  J Sebag; Jeannie Nguyen-Cuu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-10-22       Impact factor: 3.117

3.  Utilisation of optical coherence tomography and optical coherence tomography angiography to assess retinal neovascularisation in diabetic retinopathy.

Authors:  Joanna DaCosta; Devangna Bhatia; Oonagh Crothers; James Talks
Journal:  Eye (Lond)       Date:  2021-04-28       Impact factor: 3.775

Review 4.  Optical coherence tomography features of neovascularization in proliferative diabetic retinopathy: a systematic review.

Authors:  Sara Vaz-Pereira; Tiago Morais-Sarmento; Raquel Esteves Marques
Journal:  Int J Retina Vitreous       Date:  2020-06-29

5.  Characterizing Flow and Structure of Diabetic Retinal Neovascularization after Intravitreal Anti-VEGF Using Optical Coherence Tomography Angiography: A Pilot Study.

Authors:  Christof Haensli; Katrin Fasler; Daniel Barthelmes; Sandrine A Zweifel
Journal:  J Ophthalmol       Date:  2021-07-14       Impact factor: 1.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.